- Home
- USPH vs OCS Comparison
USPH vs OCS Comparison
Compare USPH & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USPH
- OCS
- Stock Information
- Founded
- USPH 1990
- OCS 2003
- Country
- USPH United States
- OCS Switzerland
- Employees
- USPH N/A
- OCS N/A
- Industry
- USPH Medical/Nursing Services
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- USPH Health Care
- OCS Health Care
- Exchange
- USPH Nasdaq
- OCS Nasdaq
- Market Cap
- USPH 1.1B
- OCS 1.0B
- IPO Year
- USPH 1992
- OCS N/A
- Fundamental
- Price
- USPH $75.23
- OCS $18.81
- Analyst Decision
- USPH Strong Buy
- OCS Strong Buy
- Analyst Count
- USPH 5
- OCS 5
- Target Price
- USPH $108.20
- OCS $39.80
- AVG Volume (30 Days)
- USPH 205.1K
- OCS 131.0K
- Earning Date
- USPH 11-05-2025
- OCS 11-10-2025
- Dividend Yield
- USPH 2.43%
- OCS N/A
- EPS Growth
- USPH 153.49
- OCS N/A
- EPS
- USPH 2.38
- OCS N/A
- Revenue
- USPH $750,948,000.00
- OCS $991,999.00
- Revenue This Year
- USPH $18.73
- OCS $32.89
- Revenue Next Year
- USPH $6.13
- OCS $1,043.16
- P/E Ratio
- USPH $31.11
- OCS N/A
- Revenue Growth
- USPH 17.51
- OCS N/A
- 52 Week Low
- USPH $62.77
- OCS $14.00
- 52 Week High
- USPH $101.20
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- USPH 44.47
- OCS 41.08
- Support Level
- USPH $66.67
- OCS $19.07
- Resistance Level
- USPH $73.93
- OCS $19.43
- Average True Range (ATR)
- USPH 3.49
- OCS 0.45
- MACD
- USPH 0.34
- OCS -0.05
- Stochastic Oscillator
- USPH 64.95
- OCS 10.75
About USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.